The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
28072531 |
120 |
Discovery of 2-(((1r,4r)-4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (Ralinepag): An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension. |
Arena Pharmaceuticals |
28523115 |
59 |
Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
Novartis Institutes For Biomedical Research |
28169162 |
86 |
Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist. |
Askat |
27876250 |
60 |
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH |
Jagiellonian University Medical College |
28105284 |
55 |
Discovery of Novel Seven-Membered Prostacyclin Analogues as Potent and Selective Prostaglandin FP and EP3 Dual Agonists. |
Ono Pharmaceutical |
26985320 |
89 |
Discovery of G Protein-Biased EP2 Receptor Agonists. |
Ono Pharmaceutical |
27133594 |
6 |
Piperidine derivatives as nonprostanoid IP receptor agonists 2. |
Toray Industries |
27107947 |
30 |
Optimization of amide-based EP3 receptor antagonists. |
Pfizer |
27020304 |
31 |
Identification and biological activity of 6-alkyl-substituted 3-methyl-pyridine-2-carbonyl amino dimethyl-benzoic acid EP4 antagonists. |
Eli Lilly |
26996371 |
27 |
Piperidine derivatives as nonprostanoid IP receptor agonists. |
Toray Industries |
27055938 |
82 |
Structural optimization and structure-functional selectivity relationship studies of G protein-biased EP2 receptor agonists. |
Ono Pharmaceutical |
26764191 |
38 |
Discovery of potent aryl-substituted 3-[(3-methylpyridine-2-carbonyl) amino]-2,4-dimethyl-benzoic acid EP4 antagonists with improved pharmacokinetic profile. |
Eli Lilly |
26725951 |
46 |
Discovery of highly potent dual EP(2) and EP(3) agonists with subtype selectivity. |
Ono Pharmaceutical |
26091726 |
41 |
Discovery and characterization of a potent and selective EP4 receptor antagonist. |
Eli Lilly |
26061158 |
136 |
A selective prostaglandin E2 receptor subtype 2 (EP2) antagonist increases the macrophage-mediated clearance of amyloid-beta plaques. |
Amgen |
24279689 |
56 |
Prostanoid receptor EP2 as a therapeutic target. |
Emory University |
24703233 |
63 |
From virtual to clinical: The discovery of PGN-1531, a novel antagonist of the prostanoid EP4 receptor. |
Argenta Discovery |
24021582 |
52 |
Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases. |
Novartis Institutes For Biomedical Research |
17098427 |
34 |
1,5-Biaryl pyrrole derivatives as EP1 receptor antagonists: Structure-activity relationships of 4- and 5-substituted benzoic acid derivatives. |
Glaxosmithkline |
17175160 |
32 |
1,5-Biaryl pyrrole derivatives as EP1 receptor antagonists. Structure-activity relationships of 6-substituted and 5,6-disubstituted benzoic acid derivatives. |
Glaxosmithkline |
24900547 |
23 |
Fluorescent Human EP3 Receptor Antagonists. |
TBA |
24900213 |
25 |
Novel 3-Oxazolidinedione-6-aryl-pyridinones as Potent, Selective, and Orally Active EP3 Receptor Antagonists. |
TBA |
19804971 |
63 |
Discovery and optimization of CRTH2 and DP dual antagonists. |
Amgen |
18359630 |
37 |
Identification of prostaglandin D2 receptor antagonists based on a tetrahydropyridoindole scaffold. |
Merck Frosst Canada |
18039575 |
35 |
Synthesis and evaluation of a gamma-lactam as a highly selective EP2 and EP4 receptor agonist. |
Emd-Serono Research Institute |
18291643 |
76 |
Structure-activity relationships and pharmacokinetic parameters of quinoline acylsulfonamides as potent and selective antagonists of the EP(4) receptor. |
Merck Frosst Centre For Therapeutic Research |
17931866 |
47 |
Synthesis and evaluation of novel pyrazolidinone analogs of PGE2 as EP2 and EP4 receptors agonists. |
Emd-Serono Research Institute |
17531488 |
44 |
Discovery of novel prostaglandin analogs of PGE2 as potent and selective EP2 and EP4 receptor agonists. |
Emd-Serono Research Institute |
16931013 |
138 |
Comparison between two classes of selective EP(3) antagonists and their biological activities. |
Merck Frosst Centre For Therapeutic Research |
15664806 |
104 |
Structure-activity relationship studies on ortho-substituted cinnamic acids, a new class of selective EP(3) antagonists. |
Merck Frosst Centre For Therapeutic Research |
15914004 |
34 |
Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: orally active prostacyclin mimetics. Part 3. |
Fujisawa Pharmaceutical |
12643927 |
164 |
Discovery of a potent and selective agonist of the prostaglandin EP4 receptor. |
Merck Frosst Centre For Therapeutic Research |
21930381 |
15 |
Synthesis, pharmacophore modeling and in vitro activity of 10,11-dihydrodibenzo[b,f]oxepine-4-carboxamide derivatives as novel and potent antagonists of the prostaglandin EP4 receptor. |
Rottapharm Madaus |
21215624 |
96 |
Naphthalene/quinoline amides and sulfonylureas as potent and selective antagonists of the EP4 receptor. |
Merck Frosst Centre For Therapeutic Research |
21126875 |
50 |
A novel series of potent and selective EP(4) receptor ligands: facile modulation of agonism and antagonism. |
Merck Frosst Canada |
21208803 |
81 |
The identification of substituted benzothiophene derivatives as PGE(2) subtype 4 receptor antagonists: From acid to non-acid. |
Merck Frosst Centre For Therapeutic Research |
21036609 |
38 |
Potent and highly selective DP1 antagonists with 2,3,4,9-tetrahydro-1H-carbazole as pharmacophore. |
Merck Frosst Centre For Therapeutic Research |
20926294 |
65 |
3-Urea-1-(phenylmethyl)-pyridones as novel, potent, and selective EP3 receptor antagonists. |
Glaxosmithkline |
20471829 |
43 |
Discovery of 4-[1-[([1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl]carbonyl)amino]cyclopropyl]benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain. |
Merck Frosst Canada |
20218623 |
68 |
Emerging targets in osteoporosis disease modification. |
Amgen |
20303752 |
143 |
1,7-Disubstituted oxyindoles are potent and selective EP(3) receptor antagonists. |
Decode Chemistry |
19836233 |
31 |
Heterocyclic 1,7-disubstituted indole sulfonamides are potent and selective human EP3 receptor antagonists. |
Decode Chemistry |
20163116 |
116 |
The discovery of 4-{1-[({2,5-dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoic acid (MK-2894), a potent and selective prostaglandin E2 subtype 4 receptor antagonist. |
Merck Frosst Centre For Therapeutic Research |
19957930 |
126 |
Structure-activity relationship studies leading to the identification of (2E)-3-[l-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a potent and selective prostanoid EP3 receptor antagonist, as a novel antiplatelet agent that |
Decode Chemistry |
19592244 |
61 |
7-Azaindole-3-acetic acid derivatives: potent and selective CRTh2 receptor antagonists. |
Novartis Institutes Of Biomedical Research |
19487124 |
39 |
Discovery of novel aminothiadiazole amides as selective EP(3) receptor antagonists. |
Glaxosmithkline |
19332369 |
43 |
Discovery of sodium 6-[(5-chloro-2-{[(4-chloro-2-fluorophenyl)methyl]oxy}phenyl)methyl]-2-pyridinecarboxylate (GSK269984A) an EP(1) receptor antagonist for the treatment of inflammatory pain. |
Glaxosmithkline |
19307115 |
89 |
Discovery of potent and selective DP1 receptor antagonists in the azaindole series. |
Merck Frosst Centre For Therapeutic Research |
19188065 |
116 |
3-Acrylamide-4-aryloxyindoles: synthesis, biological evaluation and metabolic stability of potent and selective EP3 receptor antagonists. |
Decode Chemistry |
19121942 |
57 |
Peri-substituted hexahydro-indolones as novel, potent and selective human EP3 receptor antagonists. |
Decode Chemistry |
18701276 |
97 |
Highly functionalized 7-azaindoles as selective PPAR gamma modulators. |
Merck Research Laboratories |
17300164 |
62 |
Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524). |
Merck Frosst Canada |
16529930 |
96 |
Identification of an indole series of prostaglandin D2 receptor antagonists. |
Merck Frosst Canada |
15935659 |
17 |
Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4. |
Fujisawa Pharmaceutical |
15863309 |
12 |
Lactams as prostanoid receptor ligands. Part 4: 2-Piperidones as selective EP4 receptor agonists. |
Roche Palo Alto |
15857112 |
55 |
Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists. |
Fujisawa Pharmaceutical |
15566283 |
43 |
Lactams as EP4 prostanoid receptor agonists. 3. Discovery of N-ethylbenzoic acid 2-pyrrolidinones as subtype selective agents. |
Roche Palo Alto |
15026044 |
90 |
Lactams as EP4 prostanoid receptor subtype selective agonists. Part 1: 2-Pyrrolidinones-stereochemical and lower side-chain optimization. |
Roche Palo Alto |
14552786 |
88 |
Structure-activity relationship of triaryl propionic acid analogues on the human EP3 prostanoid receptor. |
Merck Frosst Centre For Therapeutic Research |
12182865 |
88 |
Structure-activity relationship of biaryl acylsulfonamide analogues on the human EP(3) prostanoid receptor. |
Merck Frosst Centre For Therapeutic Research |
11708917 |
33 |
Synthesis and biological evaluation of prostaglandin-F alkylphosphinic acid derivatives as bone anabolic agents for the treatment of osteoporosis. |
Procter & Gamble Pharmaceuticals |
11266183 |
32 |
Structure-activity relationship on the human EP3 prostanoid receptor by use of solid-support chemistry. |
Merck Frosst Canada |
10715159 |
112 |
Design and synthesis of 13,14-dihydro prostaglandin F(1alpha) analogues as potent and selective ligands for the human FP receptor. |
Procter And Gamble Pharmaceuticals |
10509919 |
103 |
New class of biphenylene dibenzazocinones as potent ligands for the human EP1 prostanoid receptor. |
Merck Frosst Centre For Therapeutic Research |
20476840 |
9 |
Tyrosinase inhibitory effect of benzoic acid derivatives and their structure-activity relationships. |
Yonsei University |
19102654 |
32 |
Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease. |
Schering-Plough Research Institute |
15857135 |
128 |
Structural requirements for factor Xa inhibition by 3-oxybenzamides with neutral P1 substituents: combining X-ray crystallography, 3D-QSAR, and tailored scoring functions. |
Aventis Pharma Deutschland |
15801831 |
94 |
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. |
Pfizer |
12431051 |
114 |
Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 3. Structure activity relationships at C3(1,2). |
Bristol-Myers Squibb |
| 40 |
Ring Size effect in the PKC inhibitory activities of perhydroazepine analogs of balanol. |
Sphinx Laboratories |
7658450 |
20 |
Structure-based design of novel HIV protease inhibitors: carboxamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent nonpeptidic inhibitors. |
Upjohn |